PET concerns in bevacizumab treatment - Reply

被引:1
作者
Willett, CG
Duda, D
Fischman, A
Jain, RK
机构
[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA
[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
关键词
D O I
10.1038/nm0604-561b
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
引用
收藏
页码:561 / 561
页数:1
相关论文
共 1 条
[1]   Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (vol 10, pg 145, 2004) [J].
Willett, CG ;
Boucher, Y ;
di Tomaso, E ;
Duda, DG ;
Munn, LL ;
Tong, RT ;
Chung, DC ;
Sahani, DV ;
Kalva, SP ;
Kozin, SV ;
Mino, M ;
Cohen, KS ;
Scadden, DT ;
Hartford, AC ;
Fischman, AJ ;
Clark, JW ;
Ryan, DP ;
Zhu, AX ;
Blaszkowsky, LS ;
Chen, HX ;
Shellito, PC ;
Lauwers, GY ;
Jain, RK .
NATURE MEDICINE, 2004, 10 (06) :649-649